Delivery Order SPE2DE21D0007-SPE2D625F0GGS
- Not listed
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on July 11, 2025, by the Medical Supply Chain division of the Department of Defense for the supply of Anti-A Bioclone 15x10ml reagents, valued at $1,156.61. The contract employs fixed-price pricing with economic price adjustment provisions and is scheduled for ultimate completion by August 1, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used in this...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order on August 6, 2025, by the Defense Medical Supply Chain to supply ANTI-A BioclOne 15x10mL, a diagnostic reagent product. The contract is valued at $1,109.97 under a fixed-price arrangement with economic price adjustment provisions, with an ultimate completion date of August 11, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was utilized for this award, indicating open...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,871.28 for Anti-A Bioclone 15x10ml on July 21, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes fixed-price pricing with economic price adjustment and was awarded without a set-aside designation, indicating open competition. The work will be performed in Raritan, New Jersey, and is funded by the Defense Health Agency's Medical Supply Chain, which supports critical medical diagnostic...
- The U.S. Defense Department's Medical Supply Chain agency awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-B Bioclone 15x10ML on August 11, 2025, with completion targeted for August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer specializing...
- Ortho-Clinical Diagnostics, Inc. was awarded a $1,156.61 fixed-price delivery order by the Defense Medical Supply Chain on July 14, 2025, for the supply of Anti-A Bioclone 15x10ml reagent products. The contract is scheduled for ultimate completion by August 4, 2025, and will be performed at the company's facility in Raritan, New Jersey. No small business set-aside designation was utilized for this award, indicating open competition among qualified vendors. This delivery order represents a...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,963.68 by the Defense Medical Supply Chain on August 5, 2025, for Rgt Anti-A B Bcln 10mL bottles used in orthopedic blood bank applications. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and carries an ultimate completion date of August 8, 2025. Performance will be conducted at the awardee's facility in...
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, has been awarded a delivery order valued at $3,104.52 for medical diagnostic supplies and equipment designated as "ANTI-S 1X3ML." The contract was awarded on August 19, 2025, with an ultimate completion date of August 22, 2025, and utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating open competition. Performance will take place at the...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $1,037.23 to Ortho-Clinical Diagnostics, Inc. for Reagent Anti-D Bioclone 150ML Monoclonal on September 3, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating open competition. The award will be performed at the contractor's facility in Raritan, New Jersey, with an ultimate completion date of September 8, 2025. Ortho-Clinical Diagnostics, Inc., a for-profit medical...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on August 8, 2025, for the supply of Anti-A Bioclone 15x10ML reagents, with a ceiling value of $1,832.54. The contract is structured as a fixed-price delivery order with economic price adjustment provisions and is set to complete by August 29, 2025. This award was issued without a set-aside designation, indicating open competition. The place of performance is located in Raritan, New Jersey, which serves as the company's...
- SPE2DE21D0007Indefinite Delivery Contract
- SPE2DE21D0007-SPE2D625F0GGSDelivery Order
Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order is structured as a fixed-price contract with economic price adjustment provisions, typical of Ortho-Clinical Diagnostics' engagement with federal healthcare agencies. Ortho-Clinical Diagnostics specializes in providing advanced diagnostic solutions, blood bank analyzers, clinical chemistry systems, and associated consumables to federal healthcare entities including the Department of Veterans Affairs, Indian Health Service, and Defense Health Agency. The company is a self-certified HUBZone joint venture registered through May 2026 and holds multiple significant indefinite delivery vehicles with federal agencies. This delivery order for Anti-A Bioclone reagents supports critical laboratory testing infrastructure and represents a continuation of the company's established role as a key supplier of diagnostic products and technical services to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/6/25 |